Literature DB >> 17170436

Identification of residues in the ectromelia virus gamma interferon-binding protein involved in expanded species specificity.

Anthony A Nuara1, R Mark L Buller, Hongdong Bai.   

Abstract

Gamma interferon (IFN-gamma) production is important in the host response to, and recovery from, infection with Ectromelia virus (ECTV) and Vaccinia virus (VACV). The orthopoxviruses have evolved several mechanisms to subvert the IFN-gamma response. IFN-gamma-binding protein (IFN-gammaBP) is a virally encoded homologue of the host IFN-gamma receptor that blocks the effects of IFN-gamma in the infected host. Unlike the cellular receptors, whose ligand specificity is restricted to their own species, the orthopoxvirus IFN-gammaBPs bind IFN-gamma from several species. The reason for this relaxed specificity has yet to be explained. ECTV, a mouse pathogen, encodes an IFN-gammaBP that has been shown to inhibit the activity of both human and murine IFN-gamma (hIFN-gamma and mIFN-gamma, respectively). In contrast, the IFN-gammaBP from VACV is unable to inhibit mIFN-gamma, but retains activity against hIFN-gamma. To determine which region(s) in the ECTV sequence is responsible for its ability to bind to mIFN-gamma with high affinity, a series of chimeric IFN-gammaBPs, as well as individual point mutants in the ECTV sequence corresponding to the amino acid changes from the VACV sequence, were constructed. The affinities of the chimeric and point mutant IFN-gammaBPs for mIFN-gamma were tested by using surface plasmon resonance and bioassay. By using this strategy, several key residues in the ligand-binding domains of the ECTV sequence have been identified that are responsible for high-affinity binding to mIFN-gamma. Substitution of the ECTV residue at these positions in VACV resulted in a dramatic increase in the affinity of the VACV IFN-gammaBP for mIFN-gamma.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17170436     DOI: 10.1099/vir.0.82324-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  5 in total

Review 1.  Subversion of cytokine networks by virally encoded decoy receptors.

Authors:  Megan L Epperson; Chung A Lee; Daved H Fremont
Journal:  Immunol Rev       Date:  2012-11       Impact factor: 12.988

2.  Therapeutic and prophylactic drugs to treat orthopoxvirus infections.

Authors:  Scott Parker; Lauren Handley; R Mark Buller
Journal:  Future Virol       Date:  2008-11       Impact factor: 1.831

3.  Structure and mechanism of IFN-gamma antagonism by an orthopoxvirus IFN-gamma-binding protein.

Authors:  Anthony A Nuara; Leigh J Walter; Naomi J Logsdon; Sung Il Yoon; Brandi C Jones; Jill M Schriewer; R Mark Buller; Mark R Walter
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-05       Impact factor: 11.205

4.  Cross-priming induces immunodomination in the presence of viral MHC class I inhibition.

Authors:  Elvin J Lauron; Liping Yang; Jabari I Elliott; Maria D Gainey; Daved H Fremont; Wayne M Yokoyama
Journal:  PLoS Pathog       Date:  2018-02-14       Impact factor: 6.823

5.  Structural basis of chemokine sequestration by a tick chemokine binding protein: the crystal structure of the complex between Evasin-1 and CCL3.

Authors:  João M Dias; Christophe Losberger; Maud Déruaz; Christine A Power; Amanda E I Proudfoot; Jeffrey P Shaw
Journal:  PLoS One       Date:  2009-12-30       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.